10x Genomics reported a 1% increase in revenue for the fourth quarter of 2025, reaching $166.0 million, and a net loss of $16.3 million. The company also announced partnerships and collaborations aimed at expanding its AI-ready datasets for cancer research and integrating single cell and spatial tumor analysis into diagnostic workflows.

10x Genomics delivered a solid third quarter, with revenue reaching $149.0 million, a 2% sequential increase excluding one-time license and royalty revenue from the prior quarter. The company reported a net loss of $27.5 million, an improvement from the $35.8 million net loss in the same period last year. Gross margin decreased to 67% due to product mix and higher inventory write-downs, while operating expenses saw a 10% reduction.

10x Genomics reported a revenue of $172.9 million for Q2 2025, which includes a significant patent litigation settlement. Excluding this settlement, revenue decreased by 5% year-over-year, primarily due to lower instrument sales. Despite a challenging funding environment, the company achieved net income and improved its gross margin and operating income compared to the prior year.

10x Genomics reported a 10% increase in total revenue for Q1 2025, driven by a patent litigation settlement. Excluding the settlement, revenue decreased by 2% year-over-year, primarily due to lower instrument sales. The company ended the quarter with $426.9 million in cash and marketable securities and announced cost reduction initiatives.

10x Genomics experienced a 10% decrease in revenue for Q4 2024, totaling $165.0 million, and a net loss of $49.0 million, which remained consistent with the prior year. Despite the revenue decline, the company improved its gross margin and reduced operating expenses.

10x Genomics reported third-quarter revenue of $151.7 million, a 1% decrease compared to the prior year. The company experienced a net loss of $35.8 million, an improvement from the previous year's net loss of $93.0 million. They are updating their outlook for the full year 2024, now expecting revenue to be in the range of $595 million to $605 million.

10x Genomics reported a 4% increase in revenue for Q2 2024, primarily driven by consumables. The company saw strong demand for spatial and single cell consumables, fueled by product launches earlier in the year. They are updating the outlook for the full year 2024, now expecting revenue to be in the range of $640 million to $660 million.

10x Genomics reported a 5% increase in revenue for Q1 2024, driven by Spatial revenue. The company shipped four major new products and is maintaining its full year 2024 revenue guidance of $670 million to $690 million.

10X Genomics reported Q4 2023 revenue of $184.0 million, an 18% increase year-over-year. The company's gross margin decreased to 63% due to product mix, and the operating loss widened to $55.2 million. The company launched preorders for Visium HD Spatial Gene Expression and Chromium GEM-X technology.

10x Genomics reported a solid third quarter with revenue reaching $153.6 million, a 17% increase compared to the previous year, driven by strong Xenium performance. The company is raising its full year 2023 revenue guidance to $610 million to $625 million, representing 18% to 21% growth over full year 2022.

10x Genomics reported a strong second quarter with revenue of $146.8 million, a 28% increase year-over-year. The company is raising its full year 2023 revenue guidance to a range of $600 million to $620 million.

10x Genomics reported a 17% increase in revenue for the first quarter of 2023, reaching $134.3 million. The growth was primarily driven by higher revenue in the Americas and EMEA regions, with spatial revenue growth accelerating due to strong demand for Xenium and Visium CytAssist.

10x Genomics reported Q4 2022 revenue of $156.2 million, a 9% increase year-over-year. The company's operating loss was $23.1 million, and net loss was $17.2 million. They also provided full year 2023 revenue guidance of $580 million to $600 million.

10x Genomics reported revenue of $131.1 million for the third quarter of 2022, representing a 5% increase compared to the same period in 2021. The increase was primarily driven by higher volume of units sold and growth due to new customers, partially offset by unfavorable foreign exchange fluctuations. The company is maintaining its full year 2022 revenue guidance of $500 million to $520 million.

10x Genomics reported a slight decrease in revenue for the second quarter of 2022, with revenue totaling $114.6 million, a 1% decrease compared to the prior year period. The decrease was primarily driven by decreased demand due to lockdowns in China, delayed customer reorders in Europe resulting from a logistics cold-chain issue, execution challenges and unfavorable foreign exchange headwinds. The company is updating its outlook for the full year 2022 and now expects revenue to be in the range of $500 million to $520 million, representing 2% to 6% growth over full year 2021.

10x Genomics reported an 8% increase in revenue compared to the corresponding period of 2021. The increase was primarily the result of increased consumables revenue driven by growth in cumulative instruments sold and increased instrument revenue driven by sales of Chromium X Series instruments. Operating loss was $41.7 million, as compared to $10.2 million for the corresponding prior year period.

10x Genomics reported a 28% increase in revenue for Q4 2021, reaching $143.5 million. The company's operating loss was $15.8 million, and net loss was $18.4 million. They also provided full year 2022 revenue guidance of $600 million to $630 million.

10x Genomics reported a 74% increase in revenue compared to the same quarter last year, reaching $125.3 million. The company launched the Chromium X instrument and saw customer publications surpass 3,000 research papers. Despite the strong revenue growth, the company reported an operating loss of $15.9 million.

10x Genomics reported strong second-quarter results, with revenue reaching $115.8 million, a 170% increase year-over-year. The company launched Chromium X and began shipping Visium Spatial Gene Expression for FFPE, and settled litigation with Bio-Rad Laboratories, Inc.

10x Genomics reported a strong start to the year with a 47% increase in revenue compared to Q1 2020. The company launched new products and capabilities and announced the acquisition of Tetramer Shop.

10x Genomics reported a revenue of $112.2 million for Q4 2020, a 49% increase compared to Q4 2019. The company's gross margin was 83%, up from 78% in the prior year period. However, the company experienced a significant operating loss of $409.6 million, driven by a large increase in operating expenses due to in-process research and development expenses related to the ReadCoor acquisition.

10x Genomics reported a strong third quarter with a 17% increase in revenue compared to the same period last year. The company completed acquisitions of ReadCoor and CartaNA, expanding its capabilities in In Situ analysis. A follow-on public offering generated approximately $482.2 million in net proceeds.

10x Genomics reported a 23% decrease in revenue compared to the same quarter last year, totaling $42.9 million, due to COVID-19 related lab closures. Despite the challenges, the company launched several new products and expanded its Visium Clinical Translational Research Network. The gross margin increased to 77%, but the operating loss widened to $39.4 million.

10x Genomics reported a strong first quarter with revenue of $71.9 million, a 34% increase compared to the same period in 2019. The company highlighted its commitment to supporting customers in combating the COVID-19 pandemic and expressed confidence in future opportunities despite macro uncertainties. However, they withdrew their annual revenue guidance for 2020 due to the evolving environment and continued uncertainties from the impact of COVID-19.

10x Genomics reported a 49% increase in revenue for Q4 2019, reaching $75.3 million. The company's gross margin improved to 78%, and operating expenses decreased significantly. As a result, the operating loss and net loss were substantially reduced compared to the same period in the prior year.